Cancer drug target Chk1 may also be source of drug resistance
5th Sep 2005, 14:30 GMT
A study published by The Burnham Institute in the September edition of Molecular Cell reports that a cell-cycle checkpoint protein, known to be activated by an important class of anticancer drugs, may play crucial roles in both the hampering of therapeutic actions and aiding cancer cells to "recover" and start dividing again after treatment with these drugs. The study is expected to help academic researchers and biotechnology and pharmaceutical companies design drugs that combat cancer using this checkpoint protein, but with fewer side effects.
Latest news from EurekAlert! - Breaking News:
- Scientists capture nanoscale images with short and intense X-ray laser
- Mayo researchers offer evidence people with psoriasis greater risk for developing heart disease
- Mayo Clinic information about accelerated aging among people with rheumatoid arthritis
- ESSP launches project on the effects of global environmental change on human health
- Health inequalities are a growing problem worldwide
- HIV/AIDS linked to extensively drug resistant TB
- Higher death rate for heart attack patients with additional non-cardiac conditions
- Hormone linked to brain's cravings for food and other energy sources
- Key to acute lung injury lies in Ang2 protein
- Propane fuel cell passes muster at Exit Glacier Nature Center